Russian tax audit penalizes Dr. Reddy’s (NYSE: RDY) subsidiary over VAT

Rhea-AI Filing Summary

Dr. Reddy’s Laboratories Limited reports that its step-down wholly owned subsidiary, Dr. Reddy’s Laboratories LLC in Russia, has received a tax audit decision from the Interdistrict Inspectorate of the Federal Tax Service of Russia dated January 23, 2026. The authority reclassified certain marketing services as taxable, levying Value Added Tax (VAT) and quantifying a penalty of Rub million 20.09, stated as INR 24.50 million.

The company states that, based on its evaluation, this tax decision has no material impact on its financials, operations, or other activities. Dr. Reddy’s plans to evaluate filing a reply with the Russian tax authority in response to the decision and is providing this update to stock exchanges in India and the New York Stock Exchange.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

January, 2026

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x                                      Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ¨                                      No x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

EXHIBITS

Exhibit Number		Description of Exhibits
99.1		Intimation dated January 24, 2026

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED (Registrant)
Date: January 24, 2026	By:	/s/ K Randhir Singh
		Name:	K Randhir Singh
		Title:	Company Secretary

3

Exhibit 99.1

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel:       + 91 40 4900 2900 Fax:     + 91 40 4900 2999 Email: mail@drreddys.com Web:   www.drreddys.com

January 24, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is to inform that Dr. Reddy’s Laboratories LLC, Russia, a step-down wholly-owned subsidiary of Dr. Reddy’s Laboratories Limited has received tax audit decision on January 23, 2026, from The Interdistrict Inspectorate of the Federal Tax Service of Russia. The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are as hereunder:

S. No.	Name of the authority	:	The Interdistrict Inspectorate of the Federal Tax Service of Russia.
1	Nature and details of the action(s) taken, or order(s) passed	:	Dr. Reddy’s Laboratories LLC, Russia, a step-down wholly-owned subsidiary of Dr. Reddy’s Laboratories Limited received a tax audit decision from The Interdistrict Inspectorate of the Federal Tax Service of Russia.
2	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	:	Tax audit decision received by the Company on January 23,2026.
3	Details of the violation(s)/ contravention(s) committed or alleged to be committed	:	Levy of Value Added Tax (VAT) upon re-classification of marketing services as taxable services by the authority.
4	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	:	The authority has quantified a penalty of Rub million 20.09 [INR 24.50 million]. Based on our evaluation, there is no material impact on the financials, operations, or other activities of the Company

The Company will evaluate filing necessary reply to the authority in this regard.

This is for your information and records.

Thanking you,

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR